Veracyte Inc [VCYT] stock is trading at $36.12, down -0.91%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The VCYT shares have gain 1.46% over the last week, with a monthly amount glided 0.22%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Veracyte Inc [NASDAQ: VCYT] stock has seen the most recent analyst activity on October 20, 2025, when Canaccord Genuity initiated its Hold rating and assigned the stock a price target of $40. Previously, Craig Hallum started tracking the stock with Buy rating on March 20, 2025, and set its price target to $45. On December 05, 2024, downgrade downgraded it’s rating to Neutral and revised its price target to $37 on the stock. Wolfe Research started tracking the stock assigning a Outperform rating and suggested a price target of $50 on November 15, 2024. UBS initiated its recommendation with a Buy and recommended $43 as its price target on October 16, 2024. Guggenheim started tracking with a Buy rating for this stock on October 10, 2024, and assigned it a price target of $40. In a note dated February 23, 2024, Needham reiterated a Buy rating on this stock and boosted its target price from $30 to $33.
Veracyte Inc [VCYT] stock has fluctuated between $22.61 and $47.32 over the past year. Currently, Wall Street analysts expect the stock to reach $34 within the next 12 months. Veracyte Inc [NASDAQ: VCYT] shares were valued at $36.12 at the most recent close of the market. An investor can expect a potential drop of -5.87% based on the average VCYT price forecast.
Analyzing the VCYT fundamentals
Veracyte Inc [NASDAQ:VCYT] reported sales of 479.13M for the trailing twelve months, which represents a growth of 13.75%. Gross Profit Margin for this corporation currently stands at 0.67% with Operating Profit Margin at 0.03%, Pretax Profit Margin comes in at 0.06%, and Net Profit Margin reading is 0.05%. To continue investigating profitability, this company’s Return on Assets is posted at 0.02, Equity is 0.02 and Total Capital is 0.01. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 35.27 points at the first support level, and at 34.41 for the second support level. However, for the 1st resistance point, the stock is sitting at 36.97, and for the 2nd resistance point, it is at 37.81.
Ratios To Look Out For
For context, Veracyte Inc’s Current Ratio is 5.43. Further, the Quick Ratio stands at 5.10, while the Cash Ratio is 2.87. Considering the valuation of this stock, the price to sales ratio is 5.93, the price to book ratio is 2.33 and price to earnings (TTM) ratio is 108.57.
Transactions by insiders
Recent insider trading involved Febbo Phillip G., Chief Scientific & Med Officer, that happened on Oct 06 ’25 when 8349.0 shares were sold. Officer, PHILLIP FEBBO completed a deal on Oct 06 ’25 to buy 8349.0 shares. Meanwhile, Chief Commercial Officer-CLIA Leite John sold 2539.0 shares on Oct 01 ’25.
